Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.

Saved in:
Bibliographic Details
Title: Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.
Authors: Wilkinson N; Institute of Health and Society, Faculty of Medical Sciences, Newcastle University, Newcastle-upon-Tyne, UK., Tsakok T; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK; St. John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Dand N; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK., Bloem K; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands., Duckworth M; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK., Baudry D; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK., Pushpa-Rajah A; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK., Griffiths CEM; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK., Reynolds NJ; Dermatological Sciences, Institute of Cellular Medicine, Medical School, Newcastle University, and Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Barker J; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK; St. John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK., Burden AD; Institute of Infection, Immunity and Inflammation, University of Glasgow, UK., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands., Stocken D; Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Smith C; St John's Institute of Dermatology, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK; St. John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Electronic address: catherine.smith@kcl.ac.uk.
Corporate Authors: BSTOP study group, PSORT consortium
Source: The Journal of investigative dermatology [J Invest Dermatol] 2019 Jan; Vol. 139 (1), pp. 115-123. Date of Electronic Publication: 2018 Aug 18.
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1523-1747
DOI:10.1016/j.jid.2018.07.028